| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,830 | 1,926 | 15.08. | |
| 1,858 | 1,904 | 14.08. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 1,980 | 202 | |||
| 1,976 | 202 | |||
| 1,972 | 202 | |||
| 1,880 | 1.600 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idd.htm [/URL] | ||||
| 1.600 | 1,836 | |||
| 202 | 1,742 | |||
| 202 | 1,738 | |||
| 202 | 1,734 | |||
| 1.071 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.277 | 0,673 | 2.206 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | +0,214 +13,49 % | 500 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast | 420 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00... ► Artikel lesen | |
| Fr | Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares | 448 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| INNATE PHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares | 526 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced... ► Artikel lesen | |
| Mo | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | Innate Pharma plans phase 3 trial, names new medical officer | 1 | Investing.com |